KRAS and pancreatic ductal adenocarcinoma: ATM and WEE1 (DNA damage cell-cycle checkpoint protein) inhibition has been shown to decrease CXCR2 expression and surface PDL1 exposure in human pancreatic ductal adenocarcinoma (PDAC) cells with KRAS mutations [402].